CRABP2 and ovarian carcinoma: Mechanistically, we found that abnormal expression of CRABP2 can cause abnormal activity of the RA signaling pathway, leading to upregulation of HIF1α expression and increased overall metabolic activity in cells, ultimately resulting in ovarian cancer cell drug resistance.